DSPE-PEG2000-GALA
DSPE-PEG2000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG2000-GALA can be used for drug delivery.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Lipids used to prepare nanoparticles are a class of amphiphilic biomolecules that combine structural diversity, biocompatibility, and functional tunability. As the core framework of nanodelivery systems, they not only form lipid bilayers or solid matrices through self-assembly to encapsulate lipophilic or hydrophilic drugs, but can also be further subdivided according to formulation requirements into structural lipids (such as phospholipids and triglycerides), functional lipids (such as ionizable cationic lipids used for nucleic acid condensation and endosome escape), and sterically stable lipids (such as PEGylated lipids).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
SMILES
O=C(CCN1C(C(SC[C@@H](N)C(N[C@H](C(C[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC2=CNC=N2)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(C)=O)C)=O)C)=O)CC(C)C)=O)C)=O)=O)CC(C)C)=O)C)=O)CCC(O)=O)=O)C)=O)CC(C)C)=O)C)=O)CCC(O)=O)=O)C)=O)CC(C)C)=O)=O)CCC(O)=O)=O)C)=O)CC(C)C)=O)C)=O)CCC(O)=O)=O)C)=O)CC(C)C)=O)C)=O)=O)C)=O)CC(C)C)=O)C)=O)=O)=O)CC3=CNC4=C3C=CC=C4)=O)CC1=O)=O)NCCOCCOC(NCCOP(OC[C@](COC(CCCCCCCCCCCCCCCCC)=O)(OC(CCCCCCCCCCCCCCCCC)=O)[H])([O-])=O)=O.[n]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)